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Angiogenesis, the growth of new blood vessels, is a complex
process involving the proliferation, migration and protease
production of endothelial cells (Folkman and Shing, 1992).
Although there are potentially numerous angiogenic factors
(Kumar et al, 1998), considerable evidence has accumulated to
indicate that vascular endothelial growth factor (VEGF) may be
the angiogenic cytokine of central importance in human solid
tumours, including human gliomas (Plate et al, 1992; Kim et al,
1993; Millauer et al, 1994). VEGF represents a useful marker and
measurable element of glioblastoma angiogenesis (Takano et al,
1996) and is believed to play a bifunctional role in glioblastoma
biology leading to both angiogenesis and vasogenic oedema
(Dvorak et al, 1995; Zagzag, 1995).
Recently, molecular mechanisms of VEGF-induced angio-
genesis have been demonstrated. VEGF stimulates angiogenesis
through cooperative mechanisms involving the VEGF-induced
proteins in endothelial cells, tissue factor (TF), avb3 integrin and
osteopontin (OPN) (Senger, 1996). For example, VEGF induction
of TF in endothelial cells lead to the generation of active thrombin,
thus modifying the composition of the extracellular matrix (Senger
et al, 1996). VEGF induction of OPN, which is a ligand for the
avb3 integrin, facilitate endothelial cell migration (Senger et al,
1996). Multiple and complex interactions involving VEGF-
induced TF, the avb3 integrin and OPN in endothelial cells are
fundamental to the mechanism by which VEGF promotes angio-
genesis in vivo (Senger, 1996). In this study, the expression and
localization of VEGF-induced molecules, TF, OPN and avb3
integrin, in endothelial cells were investigated as angiogenesis
markers in a series of human gliomas.
MATERIALS AND METHODS
Tissue preparation
Sixty-eight patients with gliomas (23 glioblastoma, 13 anaplastic
astrocytoma, 32 low-grade astrocytoma) were included in the
current study. Brain tumour tissues and normal brain tissues (two
cases of non-tumour brain and three cases of brain distant far
from tumour) were obtained during routine surgical procedures
performed for diagnostic or therapeutic indications. A part of the
tissues was immediately fixed in 10% phosphate-buffered formalin
for 48 h, paraffin-embedded and used for routine pathological diag-
nosis and immunohistochemistry. Other parts of tissues were imme-
diately frozen with liquid nitrogen and stored at –70°C. Informed
consent was obtained from all subjects involved in the current study.
Antibodies and immunohistochemistry
The Dako LSAB Kit for mouse and rabbit primary antibody
(DAKO, Glostrup, Denmark) was used (Takano et al, 1996). Tissue
sections were deparaffined and incubated with 10% normal goat
serum in phosphate-buffered saline (PBS) for 20 min. The sections
were then incubated with a monocolonal anti-tissue factor antibody,
#4509 (American Diagnostica Inc., CT, USA) at a dilution of 1/100
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(Toagosei, Tsukuba, Japan), at a dilution of 1/100 (100 mg ml–1
IgG), a polyclonal anti-VEGF antibody, A-20 (Santa Cruz Biotech.
Inc., CA, USA) at a dilution of 1/100 (1 mg ml–1 IgG), a monoclonal
osteopontin antibody, MPIIIB10 (1) (Developmental Studies
Hybridoma Bank, IA) at a dilution of 1/100 in PBS overnight at
4°C, and a monoclonal anti-human von Willebrand factor antibody
(Dako, Glostrup, Denmark) at a dilution of 1/50 (254 mg ml–1) in
PBS for 60 min at room temperature. Chromatographically purified
mouse IgG and rabbit IgG (Dako) at the same IgG concentration
were used as negative controls. Sections were incubated with
biotin-conjugated goat anti-mouse or anti-rabbit immunogloblin
for 10 min, followed by washing in PBS for 10 min. The sections
were then incubated with peroxidase-conjugated streptavidin solu-
tion for 5 min, followed by washing in PBS for 5 min. Sections
were then stained with freshly prepared aminoethylcarbazole solu-
tion for 10 min, followed by washing for 5 min in tap water. The
sections were then counterstained with haematoxylin and mounted
with aqueous mounting media. The intracellular VEGF, TF and
OPN immunostaining was assessed separately for tumour and
endothelial cells using a semiquantitative scale (–, not detected;
+ moderate; ++ strong). In another experiment, frozen sections of
18 glioma tissues (seven glioblastoma, four anaplastic astrocytoma,
seven low-grade astrocytoma) were stained with a monoclonal
aVb3 integrin antibody, 23C6 (Santa Cruz Biotech Inc., CA, USA)
at dilution of 1/50 (4 mg ml–1 IgG).
In order to investigate the co-localization of different proteins,
glioma tissues were double stained. Briefly, tissue sections were
incubated with a blocking goat serum following incubation both
with a monocolonal TF antibody (1/100 dilution) and a poly-
clonal VEGF antibody (1/200 dilution) or a monocolonal aVb3
integrin antibody (1/50 dilution) and a polyclonal VEGF antibody
(1/200 dilution) or a monoclonal OPN antibody (1/100 dilution)
and a polyclonal VEGF antibody (1/200 dilution) for 60 min 
at room temperature. The sections were incubated with
FluoroLink™ Cy™3 labelled goat anti-rabbit IgG (H+L)
(Amersham) and FluoroLink™ Cy™2 labelled goat anti-mouse
IgG (H+L) (Amersham) at a dilution of 1/1000 for 10 min, and
observed using a fluorescence microscope.
Tumour vascular density
Vascular density was scored using the vasoproliferative compo-
nent of the MAGS (microscopic angiogenesis grading system) that
has been used to quantify angiogenesis in a variety of tumours
(Brem et al, 1972; Takano et al, 1996). The number of vessels at
200´ field (1.0 mm2) was measured in microvessel ‘hot spots’
(i.e. microscopic areas containing the most dense collections of
microvessels, as initially identified under low-power magnifica-
tion) with the use of an Olympus microscope, AHBT3 (Olympus,
Tokyo, Japan) on von Willebrand factor-stained tissue sections.
Vascular density was defined by averaging the number of vessels
in the three most vascularized areas.
Human glioma cell lines and culture conditions
The human glioma cell lines U-251 MG, U-87 MG, and A-172
were obtained from the American Type Culture Collection
(Rockville, MD, USA). The human glioma cell lines TK1, TK2,
Masu, Mori, Higa were established from glioblastoma at the
Department of Neurosurgery, University of Tsukuba. The human
glioma cell line, Becker, was a generous gift. Cells were main-
tained in modified essential medium (MEM) supplemented with
10% fetal calf serum (FCS) in a humidified atmosphere containing
5% carbon dioxide at 37°C.
Human umbilical cord vein endothelial cells (HUVECs)
harvested from umbilical cords were a generous gift from Dr
Okuda (University of Tsukuba). HUVECs were maintained with
collagen coated flasks (Iwaki Glass, Tokyo, Japan) in E300
medium (Kyokuto, Tokyo, Japan) which are designed for HUVEC
culture containing 2% FCS, heparin, alpha fibroblast growth factor
(aFGF) and epidermal growth factor (EGF).
RNA isolation and reverse transcription polymerase
chain reaction
Total RNA was extracted from 29 frozen tissues (ten glioblas-
tomas, four anaplastic astrocytomas, nine low-grade astrocy-
tomas, six normal brains) and nine glioma cell lines using RNeasy
Mini Kit (Qiagen GmbH, Germany) according to the supplier’s
recommended procedure. Quantitative reverse transcription poly-
merase chain reaction (RT-PCR) for TF and VEGF mRNA in
glioma cells and glioma tissues has been described previously
(Potgens et al, 1994). We performed RT-PCR with the
GeneAmp™ RNA PCR Kit (Perkin-Elmer Cetus, Norwalk, CT,
USA). Briefly, 1 mg of total RNA was reverse transcribed by
MuLV reverse transcriptase in the presence of random hexamer,
followed by indicated cycles of PCR reaction (95°C for 1 min,
55°C for 1 min, and 72°C for 1 min) in the presence of 2 mM TF
specific primers (30 cycles), VEGF specific primers (28 cycles),
or the b-actin-specific primers (16 cycles) as a control. The TF
primers were designed (Potgens et al, 1994), the reverse primer
(5¢-CAGTGCAATATAGCATTTGCAGTAGC-3¢) is complemen-
tary to positions 1005–980, and the forward primer (5¢-CTACT-
GTTTCAGTGTTCAAGCAGTGA-3¢) corresponds to positions
723–748 (Scarpati et al, 1987). The VEGF primers (Weindel et al,
1992) included the reverse primer (5¢-CCTGGTGAGAGATCTG-
GTTC-3¢) spanning bases 861–842 and the forward primer (5¢-
TCGGGCCTCCGAAACCATGA-3¢) spanning bases 141–160.
The b-actin primers (Ng et al, 1985) included the reverse
primer (5¢-GGAGTTGAAGGTAGTTTCGTG-3¢) spanning bases
2429–2409 and the forward primer (5¢-CGGGAAATCGTGCGT-
GACAT-3¢) spanning bases 2107–2126. The predicted sizes of the
amplified TF and b-actin DNA products were 282 and 214 bp
respectively. The VEGF primers were chosen because they ampli-
fied exons 3–8 and allowed for distinguishing between the
different VEGF splicing variants. PCR products of 516 bp and
648 bp corresponded with VEGF121 and VEGF165 respectively
(Weindel et al, 1992). The quantification of these RT-PCR prod-
ucts levels was performed on a Macintosh computer using the
public domain NIH Image program (developed at the US National
Institute of Health).
Glioma-conditioned medium induction of tissue factor
mRNA in HUVECs
One times 105 glioma cells were plated into a 6-well plate. After
incubation for 24 h in MEM with 10% FCS, the medium was
changed to serum-free MEM. After 48 h incubation, the condi-
tioned medium was harvested and the concentration of VEGF in
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Human VEGF Immunoassay (R&D systems, Minneapolis, MN,
USA). Confluent HUVECs in 25-cm2 flasks were cultured in
MCDB107 medium with and without VEGF 10 ng ml–1 and the
above-prepared glioma-conditioned medium (TK2, Becker, Mori,
A172) with and without VEGF antibody (MV303, 1/50 dilution)
for 18 h. Total RNA was extracted from cultured HUVECs as
described earlier, then TF mRNA expression was measured by RT-
PCR using TF specific primers.
Statistical analyses
Vascular density and densitomtric value of VEGF, TF and b-actin
were expressed as mean ± standard deviation (s.d.). Statistically
significant differences between tumour types were determined
using a one-way analysis of variance and the Tukey test.
Correlation between VEGF and TF expression was determined by
a Pearson correlation matrix with the confidence level determined
by Bonferroni probabilities. All P-values are two-sided; values are
considered statistically significant for P < 0.05.
RESULTS
Immunolocalization of TF and VEGF in glioma tissues
TF antigen was detected consistently in both the tumour cells 
and the endothelial cells lining tumour-associated vessels by
immunohistochemical staining of formalin-fixed sections of
astrocytic tumours. TF antigen was detected in the tumour cells of
21 out of 23 glioblastomas, six of 13 anaplastic astrocytomas, and
five of 32 low-grade astrocytomas. TF antigen was detected in the
tumour-associated vessels of 17 out of 23 glioblastomas, seven of
13 anaplastic astrocytomas, and none of 32 low grade astrocy-
tomas (Figure 1 and Table 1). VEGF antigen was also detected
consistently in both the tumor cells and the endothelial cells lining
tumour-associated vessels as described previously (Takano et al,
1996). Immunoreactivity with two VEGF antibodies, MV303 and
A20, was very similar. The expression of TF and VEGF in
endothelial cells was matched in 54 among 68 cases (+ / +: 21,
+/–: 12, –/+: 2, –/–: 33, c2 test, P = 0.0001). Furthermore, local-
ization of TF and VEGF was very similar, e.g. perinecrotic
tumour cells and endothelial cells in the invading edge of the
tumour. Moreover double staining with VEGF and TF in glioblas-
toma tissues demonstrated complete matched distribution of TF
and VEGF antigen (Figure 1, E, F). Matched distribution of TF
and VEGF was observed in 19 of 23 glioblastomas. In this study,
vessel numbers counting factor VIII staining vessels were signifi-
cantly higher in cases with TF-positive in the endothelial cells
(n = 23) compared to cases with TF-negative in the endothelial
cells (n = 45) (mean ± s.d., 60.0 ± 31.7 and 26.9 ± 25.1 respec-
tively. P < 0.0001). These results demonstrate the strong linkage
between TF and VEGF expression as a marker of angiogenic
phenotype of astrocytic tumours.
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Figure 1 VEGF and TF immunohistochemistry of human astrocytic tumours. (A, B) Glioblastomas and (C, D) low-grade astrocytomas (A, C) VEGF, (B, D) TF
staining. In glioblastomas, note the intense immunoreaction for VEGF and TF both in tumour cells and vessel walls. In low-grade astrocytomas, note no
immunoreaction for VEGF and TF in either the tumour or vessel walls. Double staining of glioblastoma with VEGF (E) and TF (F). Note the intense
immunoreaction for VEGF and TF both in tumour cells and vessel walls with very similar distribution. Scale bar: 50 mmOsteopontin and a Vb3 integrin localization in
glioblastoma microvasculature
Osteopontin was localized both in the tumour cells and in the
endothelial cells of glioblastomas, with less staining in both the
tumour and endothelial cells of anaplastic astrocytomas and low-
grade astrocytomas (Figure 2A and Table 1). Double staining with
VEGF and OPN antibody demonstrated revealed that VEGF-posi-
tive vessels were also positive for OPN (data not shown). Since
immunoreactivity with the avb3 integrin antibody we used 
was observed only in frozen sections, the number of cases for
analysis was limited. avb3 integrin was localized in the microvas-
culature of glioblastoma and anaplastic astrocytoma, but not in the
microvasculature of low grade astrocytoma and normal brain
(Figure 2B). For glioma cells, we observed immunoreactivities with
five of seven glioblastomas, one of four anaplastic astrocytomas, but
none of seven low-grade astrocytomas. Double staining with VEGF
and aVb3 integrin in glioblastoma tissues revealed that VEGF-posi-
tive vessels were also positive for aVb3 integrin (Figure 2 C, D).
TF and VEGF mRNA expression in glioma cells,
HUVECs and tissues
RT-PCR was performed to determine whether TF and VEGF
would predict the degree of malignancy and angiogenesis in
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Table 1 Summary of immunohistochemical study in human astrocytic tumours
VEGF TF OPN avb3 integrin
Tumour EC Tumour EC Tumour EC Tumour EC density
Glioblastoma 23/23 18/23 21/23 17/23 20/23 15/23 5/7 7/7 56.7 ± 31.4
100% 78% 91% 74% 87% 65% 71% 100%
Anaplastic 7/13 7/13 6/13 7/13 11/13 7/13 1/4 1/4 53.0 ± 33.4
astrocytoma 54% 54% 46% 54% 85% 54% 25% 25%
Low-grade 11/32 1/32 5/32 0/32 16/30 7/30 0/7 0/7 18.7 ± 10.7
astrocytoma 34% 3% 16% 0% 54% 23% 0% 0%
EC: endothelial cell.
A B
C D
Figure 2 Immunohistochemistry of glioblastomas. (A) Osteopontin; note the intense immunoreaction both in the tumour and vessel walls. (B) avb3 integrin;
note the intense immunoreaction in the vessel walls. Double staining with (C) VEGF and (D) avb3 integrin; note the same vessel is positive both for VEGF and
avb3 integrin. Scale bar: 50 mm
VesselTissue factor as a marker of glioma angiogenesis 1971
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Figure 3 RT-PCR analysis for the transcripts of VEGF, TF and b-actin in
tissues (A, B, C) and cell lines (D). (A) PCR amplification by sequential
cycles in the same reaction in one representative glioblastoma tissue.
(B) Measurement of densitometric units in each cycles in (A). The
exponential phase of amplification is observed with 30 cycles for TF (l),
28 cycles for VEGF (n) and 16 cycles for b-actin (s). (C) Note both VEGF
and TF mRNA expression are observed in astrocytic tumour tissues
associating with histological malignancy. (D) Note both VEGF and TF mRNA
expression is various among nine glioma cell lines (U87, Becker, TK1, TK2,
U251, A172, Masu, Mori, Higa), HUVECs and TIG (human dermal fibroblast).
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Figure 4 Correlation between tissue factor and VEGF mRNA expression in
glioma tissues evaluated by RT-PCR analysis. There is a significant
correlation between TF and VEGF expression (r = 0.62, P < 0.01)
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Figure 5 HUVEC TF mRNA induction with glioma-conditioned medium. TF
mRNA expression is not detectable in the control culture of HUVEC (medium
alone) and up-regulated with VEGF 10 ng ml–1 (VEGF 10 ng ml–1). Glioma-
conditioned medium contains a large amount of VEGF also up-regulate TF
mRNA expression (Becker CM and TK2 CM). VEGF antibody treatment,
1/50 dilution for 18 h abolished the up-regulation of TF induction (Becker CM
+ Ab, TK2 CM + Ab, VEGF + Ab). The up-regulation of TF mRNA expression
with glioma-conditioned medium contains little amount of VEGF is very little
(Mori CM and A172 CM)glioma cells and tissues. For quantitative PCR analysis, we
defined the exponential phase of amplification by sequential
cycles of PCR. Also in order to compare the relative mRNA of the
different transcripts (TF, VEGF and b-actin), amplification was
done in the same reaction for each samples (Figure 3A). The
appropriate cycles in the exponential phase of amplification for
TF, VEGF and b-actin were 30, 28 and 16 cycles respectively
(Figure 3B). The 282-bp band derived from TF mRNA was
detected in all tissues. RT-PCR analysis by VEGF-specific primers
revealed the 648- and 516-bp bands, which represent two molec-
ular forms VEGF165 and VEGF121 in almost tissues, predominantly
648-bp band. In addition, one additional band larger than 770-bp
in two of glioblastomas and one anaplastic astrocytoma was
observed. Origin of this band, however, was not determined yet.
The results presented in Figure 3C show that both TF and VEGF
mRNA levels revealed the degree of malignancy of glioma tissues.
When standardized by the amount of b-actin in lane, the relative
amounts of TF were 1.36 ± 0.48 in glioblastomas, 0.95 ± 0.90 in
anaplastic astrocytomas, 0.90 ± 0.83 in low-grade astrocytomas
and 0.17 ± 0.10 in normal brain, and the relative amounts of
VEGF165 were 1.14 ± 1.03 in glioblastomas, 0.53 ± 0.44 in
anaplastic astrocytomas, 0.30 ± 0.11 in low-grade astrocytomas
and 0.18 ± 0.25 in normal brain. There was a significant correla-
tion between the TF mRNA and VEGF mRNA levels in glioma
tissues (Figure 4, r = 0.62, P < 0.01). In the nine glioma cell lines
the correlation between the TF mRNA and VEGF mRNA levels
was weak and not significant (Figure 3D).
VEGF (10 ng ml–1) up-regulated the TF mRNA level in
HUVECs (Figure 5). Glioma cell (Becker and TK2)-conditioned
medium prepared in 48-h serum-free conditions containing a large
amount of VEGF (6.3 ng ml–1 and 5.1 ng ml–1 respectively)
measured by enzyme-linked immunosorbent assay (ELISA) up-
regulated the TF mRNA in HUVEC at the similar degree with
VEGF 10 ng ml–1. While this up-regulation was inhibited with the
anti-VEGF antibody treatment (MV303, 1/50 dilution) of Becker
and TK2 conditioned medium and VEGF (Figure 5). In contrast,
up-regulation of TF mRNA was very little with other glioma cell
(Mori and A172)-conditioned medium containing little amount of
VEGF (0.6 ng ml–1 and 0.4 ng ml–1 respectively) (Figure 5).
DISCUSSION
VEGF and TF play a key role in glioma angiogenesis
Our findings of TF localized to the tumour and endothelial cells
and the level of the expression was correlated with the histological
malignancy and the microvascular density are of interest particu-
larly in the context of recent data linking TF expression in tumour
cells and endothelial cells with angiogenesis (Contrino et al,
1996). TF expression in glioma tissues has been reported (Hamada
et al, 1996). However, the role and the mechanism of TF expres-
sion in endothelial cells has not yet been determined. TF is closely
related to angiogenesis, because TF contributes to the regulation of
blood vessel development in early embryogenesis (Carmeliet et al,
1996) and human recombinant tissue factor pathway inhibitor
inhibits the growth of cultured HUVECs by inducing apoptosis
(Hamuro et al, 1998). TF is also linked to tumour angiogenesis.
Expression of TF in the angiogenic endothelial cells may be
related to the functional requirements of the sprouting and
invading capillary during neovascularization of the tumour (Ott 
et al, 1998). Tumour growth and angiogenesis were promoted by
TF overexpression and inhibited by suppression of TF expression
(Zhang et al, 1994). TF expression in endothelial cells appears to
be a marker for tumour angiogenesis in gliomas as in breast
cancers (Contrino et al, 1996) and non-small-cell lung carcinoma
(Koomagi et al, 1998).
A strong link between VEGF and TF expression in solid
tumours has been described (Zhang et al, 1994; Koomagi et al,
1998; Ollivier et al, 1998; Shoji et al, 1998). These studies demon-
strated the close relationship between tumour TF and tumour
VEGF. Our study affords a new insight with regard to the link
between VEGF and TF in glioma angiogenesis. First, glioma-
conditioned medium containing a large amount of VEGF (Becker-
and TK2-conditioned medium) as well as VEGF antigen
(10 ng ml–1) itself up-regulated TF induction in endothelial cells
(Figure 5). The TF up-regulation was neutralized with anti-VEGF
antibody treatment of the conditioned medium (Figure 5). This
result suggests a strong link between tumour VEGF and endothe-
lial TF that is revealing of in vivo angiogenic conditions. Second,
in glioblastoma tissues TF and VEGF were co-localized both in
the tumour and the endothelial cells (Figure 1 E,F) and the expres-
sion of TF and VEGF mRNA were significantly correlated with
each together (Figure 4). Shoji et al (1998) found a strong relation-
ship between the synthesis of TF and VEGF levels in human
breast cancer cell lines. In our study, the expression of TF and
VEGF in glioma cells in vitro was not significant. VEGF in glioma
cells and TF up-regulation in endothelial cells by a paracrine
mechanism may, therefore, play a key role in glioma angiogenesis.
avb3 integrin, osteopontin and glioma angiogenesis
OPN is expressed at relatively high levels by some tumour cells,
including glioma cells (Brown et al, 1994; Saitoh et al, 1995).
OPN expression in the tumour microvasculature has not received
much attention. OPN was highly expressed in glioblastoma
microvasculture co-localizing with VEGF, but less in low-grade
astrocytoma and no expression in normal vasculature. OPN
mRNA is not detectable in control cultures of endothelial cells.
Induction of OPN mRNA in endothelial cells, resulting stimula-
tion of endothelial cell migration has been observed by VEGF
10 ng ml–1 (Senger et al, 1996). Induction of OPN expression in
endothelial cells is one of the mechanisms by which VEGF
promotes angiogenesis. Expression of avb3 integrin was observed
in small vessels of glioblastoma and anaplastic astrocytoma
tissues, but not in those of non-neoplastic brain tissues and low-
grade astrocytomas, which are consistent with a previous report
(Gladson, 1996). We showed co-localization of VEGF and avb3
integrin in the glioblastoma microvessels using double immuno-
staining (Figure 3). Time and dose-dependent induction of avb3
integrin mRNA in endothelial cells by VEGF has been reported
(Senger et al, 1996). Induction of avb3 integrin expression in
endothelial cells is likely an important element of the mechanism
by which VEGF promotes angiogenesis (Brooks et al, 1994a,
1994b). Taken together, OPN and avb3 integrin in the microvascu-
lature of malignant glioma tissues may be induced by VEGF stim-
ulation. Because OPN is an avb3 ligand, co-induction of OPN and
avb3 in enndothelial cells by VEGF are also one of the markers for
glioma angiogenesis.
In summary, the data presented here predict that VEGF and
VEGF-induced endothelial molecules TF, avb3 integrin and OPN
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marker of glioma angiogenesis. There was a strong connection
between VEGF and TF expression. VEGF and TF possess several
distinct but cooperative mechanisms involving avb3 integrin and
OPN for the regulation of glioma angiogenesis. The cumulative
effects of VEGF, TF, avb3 integrin and OPN on tumour angio-
genesis should be viewed as an interactive process rather than as
solitary events (Zucker et al, 1998). TF, integrin avb3 and OPN as
well as VEGF expression on small blood vessels in glioblastoma
tumours could be an effective target for future therapeutic
endeavours in anti-angiogenesis (Takano et al, 1994a, 1994b,
1994c; Gladson, 1996).
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